120 related articles for article (PubMed ID: 12951835)
1. Activation of p53 protein in normal and in tumor cells by a novel anticancer agent CHS 828.
Wojciechowski J; Lövborg H; Wesierska-Gadek J
Drugs Exp Clin Res; 2003; 29(2):53-67. PubMed ID: 12951835
[TBL] [Abstract][Full Text] [Related]
2. Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1.
Lövborg H; Wojciechowski J; Larsson R; Wesierska-Gadek J
Cancer Res; 2002 Aug; 62(15):4206-11. PubMed ID: 12154020
[TBL] [Abstract][Full Text] [Related]
3. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein.
Wurzer G; Herceg Z; Wesierska-Gadek J
Cancer Res; 2000 Aug; 60(15):4238-44. PubMed ID: 10945636
[TBL] [Abstract][Full Text] [Related]
4. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest.
Wesierska-Gadek J; Schloffer D; Gueorguieva M; Uhl M; Skladanowski A
Cancer Res; 2004 Jul; 64(13):4487-97. PubMed ID: 15231658
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Cell Mol Biol Lett; 2001; 6(2):117-40. PubMed ID: 11544635
[TBL] [Abstract][Full Text] [Related]
6. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L
Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695
[TBL] [Abstract][Full Text] [Related]
7. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle arrest and proapoptotic effects of the anticancer cyclodepsipeptide serratamolide (AT514) are independent of p53 status in breast cancer cells.
Soto-Cerrato V; Montaner B; Martinell M; Vilaseca M; Giralt E; Pérez-Tomás R
Biochem Pharmacol; 2005 Dec; 71(1-2):32-41. PubMed ID: 16298346
[TBL] [Abstract][Full Text] [Related]
10. Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells.
Li YX; Lin ZB; Tan HR
Acta Pharmacol Sin; 2004 Jan; 25(1):76-82. PubMed ID: 14704126
[TBL] [Abstract][Full Text] [Related]
11. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.
Hsu TS; Chen C; Lee PT; Chiu SJ; Liu HF; Tsai CC; Chao JI
Cancer Chemother Pharmacol; 2008 Oct; 62(5):799-808. PubMed ID: 18193228
[TBL] [Abstract][Full Text] [Related]
12. Novel triterpenoid 25-hydroxy-3-oxoolean-12-en-28-oic acid induces growth arrest and apoptosis in breast cancer cells.
Rabi T; Wang L; Banerjee S
Breast Cancer Res Treat; 2007 Jan; 101(1):27-36. PubMed ID: 17028990
[TBL] [Abstract][Full Text] [Related]
13. Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences.
Whitacre CM; Hashimoto H; Tsai ML; Chatterjee S; Berger SJ; Berger NA
Cancer Res; 1995 Sep; 55(17):3697-701. PubMed ID: 7641178
[TBL] [Abstract][Full Text] [Related]
14. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
Bravo SB; García-Rendueles ME; Seoane R; Dosil V; Cameselle-Teijeiro J; López-Lázaro L; Zalvide J; Barreiro F; Pombo CM; Alvarez CV
Clin Cancer Res; 2005 Nov; 11(21):7664-73. PubMed ID: 16278386
[TBL] [Abstract][Full Text] [Related]
15. Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts.
Wesierska-Gadek J; Wang ZQ; Schmid G
Cancer Res; 1999 Jan; 59(1):28-34. PubMed ID: 9892179
[TBL] [Abstract][Full Text] [Related]
16. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer.
Shankar S; Srivastava RK
Int J Oncol; 2007 Apr; 30(4):905-18. PubMed ID: 17332930
[TBL] [Abstract][Full Text] [Related]
17. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells.
Pani G; Bedogni B; Anzevino R; Colavitti R; Palazzotti B; Borrello S; Galeotti T
Cancer Res; 2000 Aug; 60(16):4654-60. PubMed ID: 10969820
[TBL] [Abstract][Full Text] [Related]
18. Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro.
Hansen CM; Hansen D; Holm PK; Larsson R; Binderup L
Anticancer Res; 2000; 20(6B):4211-20. PubMed ID: 11205250
[TBL] [Abstract][Full Text] [Related]
19. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells.
Cui Q; Yu JH; Wu JN; Tashiro S; Onodera S; Minami M; Ikejima T
Acta Pharmacol Sin; 2007 Jul; 28(7):1057-66. PubMed ID: 17588343
[TBL] [Abstract][Full Text] [Related]
20. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
